Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 27, 1997 - Issue 10
Submit an article Journal homepage
407
Views
45
CrossRef citations to date
0
Altmetric
Research Article

Rifampin and rifabutin and their metabolism by human liver esterases

C. A. JAMIS-DOW Laboratory of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administrat ion, Rockville, MD 20850, USA
,
A. G. KATKI Laboratory of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administrat ion, Rockville, MD 20850, USA
,
J. M. COLLINS Laboratory of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administrat ion, Rockville, MD 20850, USA
&
R. W. KLECKER* Laboratory of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administrat ion, Rockville, MD 20850, USA
Pages 1015-1024 | Published online: 22 Sep 2008

References

  • ACOCELLA, G., 1978, Clinical Pharmacokinetics of rifampicin. Clinical Pharmacokinetics, 3, 108–127.
  • ACOCELLA, G., BoNotto, L., MAINARDI M., MARGAROLI, P. and Nicous, F. B., 1974, Kinetic studies on rifampicin. III. Effect of phenobarbital on the half-life of the antibiotic. Tijdschr Gastroentero 17, 151–158.
  • ALDRIDGE W. N., 1953, Serum esterases: Two types of esterases (A and B) hydrolyzing para-nitrophenylacetate, propionate, and a method for their determination. Biochemical Journal, 53, 110–119.
  • BACIEWICZ, A. M., SELF, T. H. and BEKEMEYER, W. B., 1987, Update on rifampin drug interactions. Archives of Internal Medicine, 147, 565–568.
  • BROGDEN, R. N. and FITTON, A., 1994, Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs, 47, 983–1009.
  • COCCHIARA, G., STROLIN BENEDETTI, M., VICARIO, G. P., BALLABIO M., GIOIA, B., VIOGLIO, S. and VIGEVANI, A., 1989, Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica, 19, 769–780.
  • FURFSZ, S., 1970, Chemical and biological properties of rifampicin. Antibiotica et Chemotherapia, 16, 316–351.
  • FURESZ, S., Scorn R., PALLANZA, and MAPELLI, E., 1967, Rifampicin: a new rifamycin. 3. Absorption, distribution, and elimination in man. Arzneimittelforschung, 17, 534–537.
  • GRANGE, J. M., WINSTANLEY, P. A. and DAVIES, P. D., 1994, Clinically significant drug interactions with antituberculosis agents. Drug Safety, 11, 242–251.
  • IATSIMIRSKAIA, E., TULEBAEV S., STOROZHUK, E., UTKIN I., SMITH, B. A., GERBER, N. and KOUDRIAKOVA, T., 1997, Metabolism of rifabutin in human enterocyte and liver microsomes : kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clinical Pharmacology and Therapeutics, 61, 554–562.
  • JAMIS -DOW, C. A., KLECICER, R. W., KATKI, A. G. and COLLINS, J. M., 1995, Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemotherapy and Pharmacology, 36, 107–114.
  • LEWIS, R. C., HAIFIELD, N. Z. and NARANG, P. K., 1991, A sensitive method for quantitation of rifabutin and its desacetyl metabolite in human biological fluids by high-performance liquid chromato-graphy (HPLC). Pharmaceutical Research, 8, 1434–1440.
  • MAE, T., HOSOE, K., FUJII, K., YAMASHITA, K., YAMANE, T., HIDAKA T.and OASHI, T., 1996, In vitro metabolism of a rifamycin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoform. Xenobiotka, 26, 793–802.
  • MAGGI, N., FURESZ, S., PALLANZA, R. and PELIZZA, G., 1969, Rifampicin desacetylation in the human organism. Arzneimittelforschung, 19, 651–654.
  • MAGGI, N., VIGEVANI, A. and PALLANZA, R., 1968, Desacetyl-rifamycins : preparation and antibacterial properties. Experientia, 24, 209–211.
  • MANDELL G. L. and PETRI, JR., W. A., 1996, Drugs used in the chemotherapy of tuberculosis, Mycobacterium avium complex disease and leprosy. In Goodman and Gilman' s The Pharmacological Basis of Therapeutics, 9th edn, edited by Joel G. Hardman, Lee E. Limbird, Perry B. Molinoff, Raymond W. Ruddon and Alfred Goodman Gilman (New York: McGraw-Hill), pp. 1155–1174.
  • The Merck Index, 12 edn, 1996, edited by S. Budavari (Rahway: Merck & Co.), pp. 1413–1414.
  • PARKINSON, A., 1996, Biotransformation of xenobiotics. In Casaret & Doull's Toxicology: The Basic Science of Poisons, 5th edn, edited by C. D. Klaassen (New York: McGraw-Hill), pp. 113–186.
  • SKINNER, M. H., HSIEH, M., TORSETH, J., PAULOIN, D., BHATIA, G., HARKONEN, S., MERIGAN, T. C. and BLASCHKE, T. F., 1989, Pharmacokinetics of rifabutin. Antimicrobial Agents and Chemotherapy, 33, 1237–1241.
  • STROLIN BENEDETTI, M. and DOSTERT, P., 1994, Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environmental Health Perspectives, 102 (suppl. 9), 101–105.
  • TRAPNELL, C. B., JAmis -Dow, C., KLECKER, R. W. and COLLINS, J. M., 1997, Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P450 3A4: relevance to clinical interaction with fluconazole. Antimicrobial Agents and Chemotherapy, 41, 924–926.
  • VITAL DURAND, D., HAMPDEN, C., BOOBIS, A. R., PARK, B. K. and DAVIES, D. S., 1986, Induction of mixed function oxidase in man by rifapentine (MDL 473), a long-acting rifamycin derivative. British Journal of Clinical Pharmacology, 21, 1–7.
  • WEBER, A., OPHEIM, K. E., SMITH, A. L. and WONG, K., 1983, High-pressure liquid chromatographic quantitation of rifampin and its two major metabolites in urine and serum. Review of Infectious Diseases, 5 (suppl. 3), S433–439.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.